Mitral regurgitation Medical Services in China

Mitral regurgitation, also known as mitral insufficiency or mitral valve incompetence, is a common valvular heart disease characterized by improper closure of the mitral valve during ventricular systole, resulting in retrograde blood flow from the left ventricle into the left atrium. This hemodynamic abnormality may arise from structural defects—such as leaflet prolapse, chordal rupture, or annular dilation—or functional causes linked to left ventricular remodeling, often secondary to ischemic cardiomyopathy or dilated cardiomyopathy. Clinical presentation ranges from asymptomatic murmurs detected incidentally to progressive dyspnea, fatigue, orthopnea, and, in advanced stages, pulmonary congestion or right-heart failure. Diagnosis relies on transthoracic echocardiography (TTE), supplemented by transesophageal echocardiography (TEE), cardiac MRI, or invasive hemodynamic assessment when indicated. Management spans medical optimization (e.g., diuretics, beta-blockers, ACE inhibitors) to definitive intervention—including surgical mitral valve repair (preferred over replacement when feasible) or transcatheter edge-to-edge repair (e.g., TEER/MitraClip)—tailored to severity, etiology, anatomy, and patient comorbidities.

China offers compelling advantages for international patients seeking high-quality care for mitral regurgitation. Leading cardiovascular centers—such as Fu Wai Hospital (National Center for Cardiovascular Diseases), Shanghai Ruijin Hospital, and Beijing Anzhen Hospital—combine deep expertise in complex valve surgery with extensive experience in minimally invasive techniques and robotic-assisted procedures. These institutions utilize state-of-the-art imaging (3D TEE, real-time intraoperative echo), next-generation transcatheter devices, and multidisciplinary Heart Teams certified by international standards. Over 15,000 mitral valve interventions are performed annually across top-tier hospitals, with published 30-day mortality rates for repair under 1.5% and 5-year survival exceeding 92% in appropriately selected cases. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising clinical rigor—making advanced care significantly more accessible. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital credentials, coordinating consultations with board-certified cardiothoracic surgeons, providing itemized, transparent pricing in advance, arranging visas and accommodation, and offering end-to-end support—from pre-travel preparation through postoperative follow-up coordination.

Treatment Options & Itemized Cost Breakdown: Mitral Regurgitation (Cardiovascular Department)

I. Non-Surgical / Conservative Management

*Indicated for asymptomatic mild-to-moderate MR, compensated LV function, or high surgical risk.*

• •Pharmacotherapy (3–6 months trial)

- Beta-blockers (e.g., bisoprolol): $8–$22/month - Diuretics (e.g., furosemide): $4–$15/month

• •Monitoring & Diagnostic Fees (per 6-month cycle)

- NT-proBNP assay: $25–$40 - 12-lead ECG + Holter monitoring: $35–$65 - Serum creatinine, electrolytes, LFTs: $20–$35 *Total annual conservative care (meds + monitoring): $320–$780*

II. Surgical & Interventional Options

*Eligibility: Symptomatic severe MR (EROA ≥40 mm², RVol ≥60 mL), LV EF ≤60%, or progressive LV dilation (LVEDD ≥60 mm).*

• •Mitral Valve Repair (Gold Standard)

- Procedure (on-pump, robotic-assisted or sternotomy): $8,900–$14,200 - ICU stay (3–5 days): $1,800–$2,700 - Hospitalization (10–14 days total): $2,200–$3,400 *Total range: $14,050–$22,000*

• •Transcatheter Edge-to-Edge Repair (TEER; e.g., MitraClip)

- Procedure (including device + fluoroscopy suite): $18,500–$24,800 - ICU (1–2 days) + ward stay (5–7 days): $1,450–$2,100 *Total range: $21,270–$28,850*

• •Mitral Valve Replacement (MVR)

- Bioprosthetic valve: $12,400–$17,900 *(Includes pre-op, surgery, ICU, and 12-day hospitalization)*

III. Special/Complex Scenarios

• •MR with Severe Pulmonary Hypertension (mPAP >55 mmHg): Requires right heart catheterization ($850–$1,200) + targeted PAH therapy ($1,100–$2,300/month) prior to valve intervention.
• •Concomitant Atrial Fibrillation & Stroke Risk: Left atrial appendage occlusion (LAAO) added to TEER/MVR (+$3,800–$5,200).
• •Reoperative MR (prior valve surgery): 20–30% higher procedural cost due to adhesions and complexity (+15–25% across all components).

IV. Quick Selection Guide

• •<65 years, no comorbidities, severe primary MR: Surgical repair — optimal durability, lowest long-term cost.
• •≥75 years, frailty/COPD/diabetes, severe MR: TEER — avoids sternotomy, faster recovery, lower 30-day mortality.
• •Budget-constrained (<$10,000 USD): Conservative management + strict serial monitoring, only if asymptomatic and stable.
• •Secondary MR with LVEF <30%: GDMT optimization first (6 months), then reassess — valve intervention rarely beneficial without myocardial recovery.
• •Acute severe MR (e.g., chordal rupture): Urgent surgical repair — costs escalate 18–22% if delayed beyond 48 hours.